OPKO acquires dry eye treatment

Article

OPKO Health has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound, civamide, with potential applications for the treatment of dry eye.

OPKO Health has acquired exclusive worldwide rights for ophthalmic uses to a topical clinical stage compound, civamide, with potential applications for the treatment of dry eye.

The compound is a proprietary TRPV-1 receptor modulator and neuronal calcium channel blocker and is currently undergoing Phase III clinical trials, as an intra-nasal formulation, to treat various types of pain. Increased tear production was observed in over 50% of the trial patients receiving civamide and no systemic side effects were recorded. Preliminary investigations suggest that civamide's effects on tear production result from its ability to modify signal transduction pathways present in the human lacrimal gland.

Terms of the agreement have not been disclosed.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.